Kronos Bio (KRON) said in a filing Friday it has agreed to terminate a collaboration and license agreement with Genentech, voiding Kronos' rights to all intellectual property generated under two discovery research programs under the partnership.
Kronos said it will transfer to Genentech all small molecule compounds, materials and data generated in connection with the programs, excluding Kronos' proprietary drug discovery platform.
The company also said it has made a one-time payment for the termination but did not disclose its figure.
Shares of the company were down over 4% in recent Friday premarket activity.
Price: 0.88, Change: -0.04, Percent Change: -4.35
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.